Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients

Abstract excerpt

BACKGROUND: Multiple sclerosis (MS) is a heterogeneous disease. In order to understand the partial responsiveness to IFNbeta in Relapsing Remitting MS (RRMS) we studied the pharmacological effects of IFNbeta therapy. METHODOLOGY: Large scale gene expression profiling was performed on peripheral blood of 16 RRMS patients at baseline and one month after the start of IFNbeta therapy. Differential gene expression was...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Immune Response and Inflammation
• Share to Multiple Sclerosis Research Studies
• Share to Rheumatoid Arthritis Research and Therapies